Stem Cell Theranostics has developed what it calls “clinical trials in a dish,” with the goal of weeding out toxic compounds early in development and saving pharmaceutical companies, patients and hospitals billions of dollars. Particularly, it’s focused on heart disease. The biotech is developing technology that would let researchers grow heart cells in a dish from skin cell-derive pluripotent stem cells. That would give them a cheaper, faster and more accurate way to screen drugs for efficacy and toxicity.
Help employers find you! Check out all the jobs and post your resume.
